Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

32
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
32
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

30
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
30
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

32
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
32

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe Hypertension: Evaluation and Treatment.

American family physician·2026
Same author

Blue-Gray Nails and Skin.

American family physician·2026
Same author

Heat-Related Illnesses.

American family physician·2026
Same author

Palpitations: Evaluation, Management, and Wearable Smart Devices.

American family physician·2024
Same author

Managing Selected Chronic Conditions in Hospitalized Patients.

American family physician·2024
Same author

Cardiovascular Disease: Atrial Fibrillation and Atrial Flutter.

FP essentials·2024
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Related Experiment Video

Updated: Sep 10, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K

Heart Failure With Reduced Ejection Fraction: Medical Management.

Robert L Gauer1, Adam Rifaat1, Ashley M Foulkrod1

  • 1Womack Army Medical Center, Fort Bragg, North Carolina.

American Family Physician
|August 20, 2025
PubMed
Summary
This summary is machine-generated.

Guideline-directed medical therapy, including four key drug classes, improves survival and quality of life for heart failure with reduced ejection fraction (HFrEF) patients. Adjustments and secondary therapies are vital for persistent symptoms and managing side effects.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Related Experiment Videos

Last Updated: Sep 10, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.6K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.0K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.7K

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Treatment

Background:

  • Heart failure with reduced ejection fraction (HFrEF) management has advanced, leading to increased patient survival.
  • Current treatment aims to reduce mortality, hospitalizations, and symptoms, while enhancing functional status and quality of life.

Purpose of the Study:

  • To outline current guideline-directed medical therapy (GDMT) for HFrEF.
  • To discuss secondary therapies, management of adverse effects, and the role of iron replacement and device therapies.

Main Methods:

  • Review of established and emerging treatments for HFrEF.
  • Emphasis on guideline-recommended pharmacological interventions.
  • Inclusion of device therapies and diagnostic tools like point-of-care ultrasonography.

Main Results:

  • GDMT, including renin-angiotensin system/neprilysin inhibitors, beta blockers, mineralocorticoid receptor antagonists, and SGLT-2 inhibitors, is proven to reduce morbidity and mortality.
  • Secondary therapies and intravenous iron replacement improve outcomes in specific patient groups.
  • Device therapies address sudden cardiac death risk, and ultrasonography aids diagnosis and treatment assessment.

Conclusions:

  • Comprehensive management of HFrEF involves timely initiation and titration of GDMT.
  • Personalized treatment strategies, including secondary therapies and supportive interventions, are crucial for optimizing patient outcomes.
  • Ongoing monitoring and adjustment of therapy are essential for managing adverse effects and improving quality of life in HFrEF patients.